Skip to content
Getting Under the Skin With GPP: Understanding and Treating a Rare Dermatologic Disorder - Live Webcast September 28, 2023 Pretest (ID: i879-2)
To assist us in evaluating the effectiveness of this activity, please complete the following pretest.
*
1.
Which of the following best describes your profession?
(Required.)
MD/DO
NP
PA
RN
PharmD/RPh
Other (please specify)
*
2.
Which of the following best describes your specialty?
(Required.)
Dermatology
Primary Care
Other (please specify)
*
3.
How confident are you in the management of patients with GPP in your practice?
(Required.)
Very confident
Confident
Little confidence
No confidence
*
4.
GPP is characterized by which of the following?
(Required.)
Gradual appearance of intensely pruritic, dome-shaped papules
Sudden eruption of painful, pruritic, neutrophil-rich pustules
Fever and malaise followed a day or two later by pus-filled lesions
Rapid onset of widespread, scaly, fluid-and-blood-filled cysts
*
5.
Which of the following is the most common comorbidity of GPP?
(Required.)
Atopic dermatitis
Plaque psoriasis
Type 2 diabetes
von Zumbusch psoriasis
*
6.
Populations that are more frequently affected by GPP include which of the following?
(Required.)
Men and Asians
Men and Blacks
Women and Asians
Women and Blacks
*
7.
GPP is an autoimmune disorder caused mostly by mutations in which gene?
(Required.)
CARD14
IL17A
IL31RA
IL36RN
*
8.
IL-36 receptor antagonists improve or resolve symptoms and sequelae of GPP by binding to the IL-36 receptor, which prevents what?
(Required.)
IL-36 α, β, and γ isoforms from dimerizing the IL-1RAcP receptor
Downstream signaling of disease-specific proinflammatory cytokines
Activation of neutrophil-derived proteases that stimulate IL-36
Recruitment of self-reactive dendritic, B-, and T-cells into the skin
*
9.
In the Effisayil 1 trial of 53 patients with GPP, what percentage of patients taking spesolimab achieved the primary endpoint of GPPGA score of 0 or 1 (clear or almost clear skin) by week 1 vs 6% of those taking placebo?
(Required.)
67%
54%
35%
27%
*
10.
Andrea, a 42-year-old woman with a history of GPP, lives in fear of when her next flare might occur. She has been relying on oral corticosteroids to prevent flare and is afraid to go off them because she knows that systemic steroid withdrawal is a common trigger for flare. Which treatment might be best to prevent GPP flare?
(Required.)
Cyclosporine + anti-TNF-α
Anti-IL-17 biologic
Anti-IL-36 spesolimab
Anti-IL-36 imsidolimab
*
11.
An online survey of 66 people living with GPP in the United States found which of the following two activities were most severely affected by GPP flare?
(Required.)
Physical activity and intimacy
Important life events and socializing
Running errands and household chores
*
12.
Contact Information
(Required.)
Full Name
Email address
Phone number